Literature DB >> 16397206

Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer.

Ann Marie Egloff1, Laura A Vella, Olivera J Finn.   

Abstract

Uncontrolled cell division is an indispensable event in tumor progression, and numerous molecules involved in this process have been the focus of intense investigation in tumor biology. Cyclins, molecules that orchestrate normal cell cycle progression, are abnormally overexpressed in various human cancers. We review evidence that the immune system recognizes some abnormally expressed cyclins as tumor antigens, such as cyclin B1, and we analyze the potential of cyclins D, E, and A to serve a similar function in cancer immunosurveillance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16397206     DOI: 10.1158/0008-5472.CAN-05-3389

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

Review 1.  Posttranscriptional regulation of cancer traits by HuR.

Authors:  Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-05-06       Impact factor: 9.957

2.  Higher levels of antibodies to the tumour-associated antigen cyclin B1 in cancer-free individuals than in patients with breast cancer.

Authors:  J P Pandey; E Kistner-Griffin; A M Namboodiri; M Iwasaki; Y Kasuga; G S Hamada; S Tsugane
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

3.  Transcriptome analysis of neoplastic hemocytes in soft-shell clams Mya arenaria: Focus on cell cycle molecular mechanism.

Authors:  Ahmed Siah; Patty McKenna; Franck C J Berthe; Luis O B Afonso; Jean-Michel Danger
Journal:  Results Immunol       Date:  2013-11-01

Review 4.  The dawn of vaccines for cancer prevention.

Authors:  Olivera J Finn
Journal:  Nat Rev Immunol       Date:  2017-12-27       Impact factor: 53.106

5.  A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.

Authors:  Ahmad A Tarhini; Theofanis Floros; Hui-Min Lin; Yan Lin; Zahra Rahman; Madeeha Ashraf; Priyanka Vallabhaneni; Cindy Sander; Uma N M Rao; Monica Panelli; William A LaFramboise; John M Kirkwood
Journal:  Melanoma Res       Date:  2017-10       Impact factor: 3.599

Review 6.  Human Tumor Antigens Yesterday, Today, and Tomorrow.

Authors:  Olivera J Finn
Journal:  Cancer Immunol Res       Date:  2017-05       Impact factor: 11.151

7.  Fever-range whole body thermotherapy combined with oxaliplatin: a curative regimen in a pre-clinical breast cancer model.

Authors:  R Wanda Rowe; Frederick R Strebel; Jesse M Proett; Wanleng Deng; Diana Chan; Guangan He; Zahid Siddik; Joan M C Bull
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

8.  Expression of Hsp90α and cyclin B1 were related to prognosis of esophageal squamous cell carcinoma and keratin pearl formation.

Authors:  Tingyuan Huang; Size Chen; Hongyu Han; Huadan Li; Zhizhou Huang; Jianming Zhang; Qiangbin Yin; Xiaojie Wang; Xiaojiao Ma; Peijuan Dai; Danping Duan; Fei Zou; Xuemei Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

9.  Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1-positive tumors in p53 (-/-) mice.

Authors:  Laura A Vella; Min Yu; Amy B Phillips; Olivera J Finn
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

Review 10.  Autoantibodies to tumor-associated antigens: reporters from the immune system.

Authors:  Eng M Tan; Jianying Zhang
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.